Arizona Cancer Center Gets Bristol-Myers Squibb Grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content